



**Viyash Scientific Limited**

(Formerly known as Sequent Scientific Limited)

Registered Office:

3<sup>rd</sup> Floor, Srivalli's Corporate, Plot No.290, Road No.6,  
Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills,  
Hyderabad, Shaikpet, Telangana, India-500033

T: +91 40 23635000,

E: investorrelations@viyash.com

Website: www.viyash.com

CIN: L99999TS1985PLC196357

May 19, 2026

To,

**BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai - 400 001

**National Stock Exchange of India Limited**

Exchange Plaza,  
Bandra-Kurla Complex,  
Bandra (East),  
Mumbai - 400 051

**Scrip code: 512529**

**Scrip code: VIYASH**

Dear Sir/ Madam,

**Subject: Investor Presentation for FY 2025-26**

Dear Sir/Madam,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Investor Presentation on Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026.

This is for your information and appropriate dissemination.

Thanking you,

Yours faithfully,

For **Viyash Scientific Limited**

(Formerly known as Sequent Scientific Limited)

**Yoshita Vora**

**Company Secretary & Compliance Officer**

# INVESTOR PRESENTATION

---

## Q4 FY26

VIYASH SCIENTIFIC LIMITED

May 19, 2026

“Fiscal Year 2026 has been a transformative year for Viyash Scientific, marked by the successful integration of our facilities, operations, and corporate functions into one unified platform. Q4 was the strongest quarter in the Company’s history, with merger synergies beginning to reflect meaningfully in our financial performance. The integrated platform has strengthened execution, improved operating leverage, and enhanced our resilience amidst ongoing geopolitical and maritime disruptions. We continue to navigate these challenges through disciplined asset utilization, cost controls, and agile pricing strategies. As we enter FY27, we are excited about our product pipeline and growth roadmap. With a significantly deleveraged balance sheet, we are also actively evaluating selective inorganic opportunities to further strengthen our platform and create long-term value“.




**Dr Hari Babu Bodepudi**  
Viyash Scientific Limited

---

# Q4FY26 Financial Snapshot

# Viyash Scientific : Q4 FY26 Performance Highlights



All values in ₹ Mn



Notes: 1. EBITDA are adjusted for ESOP costs

# Viyash : FY26 Performance Highlights

All values in ₹ Mn



# Revenue Performance Key highlights

All values in ₹ Mn

Revenue Distribution	Q4			Q3		12M		
	FY26	FY25	YoY %	FY26	QnQ %	FY26	FY25	YoY %
<b>Formulations</b>	<b>4,991</b>	<b>3,893</b>	<b>28%</b>	<b>4,809</b>	4%	<b>18,657</b>	<b>15,828</b>	18%
Europe	1,733	1,365	27%	1,790	-3%	6,682	5,614	19%
Emerging Markets	1,725	1,429	21%	1,630	6%	6,305	5,142	23%
India	379	263	44%	401	-5%	1,405	1,155	22%
USA	1,154	837	38%	988	17%	4,266	3,916	9%
<b>APIs</b>	<b>3,836</b>	<b>3,649</b>	<b>5%</b>	<b>3,658</b>	5%	<b>14,906</b>	<b>13,747</b>	<b>8%</b>
Other Sales	184	115		85		423	372	
<b>Global Sales</b>	<b>9,011</b>	<b>7,658</b>	<b>18%</b>	<b>8,552</b>	<b>5%</b>	<b>33,987</b>	<b>29,946</b>	<b>13%</b>
One Offs #		-		-		(56)	(74)	
Adjustment* - Ind AS 29*	189	66		33		273	196	
<b>Reported Sales</b>	<b>9,200</b>	<b>7,723</b>	<b>19%</b>	<b>8,584</b>	<b>7%</b>	<b>34,203</b>	<b>30,068</b>	<b>14%</b>


\*Adjustment on account of hyperinflation in Turkey as per Ind AS 29

# Provision for customer claim on shipments in prior years


# Sustained Sales Growth with Consistent EBITDA Expansion

All values in ₹ Mn


## SALES




## GROSS MARGIN



## EBITDA<sup>1</sup>



## Net Debt to EBITDA<sup>1</sup>



# Viyash Consolidated Financials


All values in ₹ Mn

Particulars	Q4 FY26	Q4 FY25	Grw YoY %	Q3 FY26	Grw QnQ %	FY26	FY25	Grw YoY %
Revenue from Operations	9,200	7,723	19.1%	8,584	7.2%	34,203	30,068	13.8%
Material Consumption	(4,128)	(3,648)		(3,909)		(15,627)	(14,702)	
<b>Gross Margin</b>	<b>5,071</b>	<b>4,075</b>	<b>24.4%</b>	<b>4,675</b>	<b>8.5%</b>	<b>18,576</b>	<b>15,367</b>	<b>20.9%</b>
% Gross margin	55.1%	52.8%		54.5%		54.3%	51.1%	
Employee Benefit Expenses	(1,445)	(1,275)	13.3%	(1,298)	11.3%	(5,293)	(4,959)	6.7%
Operating Expenses	(1,689)	(1,578)	7.0%	(1,532)	10.3%	(6,378)	(5,984)	6.6%
Exchange Gain / (Loss)	63	(1)		8		120	(23)	
<b>EBITDA<sup>1</sup></b>	<b>2,001</b>	<b>1,221</b>	<b>63.9%</b>	<b>1,854</b>	<b>7.9%</b>	<b>7,025</b>	<b>4,400</b>	<b>59.6%</b>
% EBITDA	21.7%	15.8%		21.6%		20.5%	14.6%	
ESOP cost	(53)	(99)		(79)		(362)	(561)	
Exceptional Items	0	(744)		(413)		(442)	(816)	
IndAS 29 Adjustment	(42)	6		(5)		(17)	29	
Other Income	96	102		127		315	329	
Finance Cost	(145)	(207)		(168)		(692)	(864)	
Depreciation	(604)	(647)		(585)		(2,336)	(2,387)	
<b>Earnings Before Tax</b>	<b>1,252</b>	<b>(367)</b>	<b>440.6%</b>	<b>731</b>	<b>71.4%</b>	<b>3,490</b>	<b>132</b>	<b>2569.4%</b>
% Earning Before Tax	13.6%	-4.8%		8.5%		10.2%	0.4%	
Taxes	(589)	45		(246)		(1,244)	26	
<b>Earnings After Tax</b>	<b>664</b>	<b>(322)</b>	<b>305.5%</b>	<b>485</b>	<b>36.9%</b>	<b>2,246</b>	<b>158</b>	<b>1334.0%</b>

- Finance Cost reduction on account of the run-down of debt.
- Tax adjustments of Rs. 160mn because of one of the subsidiaries moving to new tax regime.

# Business Update





## Facility Inspections

- ✓ 2 Regulatory Audits
- ✓ 36 Customer audits



## Products Filed

- ✓ **4 APIs** – USDMF (2), JDMF (1). CA DMF (1)
- ✓ 3FDFs (USA)



## Regulatory Approvals

- ✓ **4 APIs:** (USDMF-1 ; EDQM-1; JDMF-1, ANVISA-1)
- ✓ **4 FDFs-** USFDA



## Validations Completed

- ✓ **6 APIs**
- ✓ **1 FDF**



## Launches

- ✓ **5 APIs** (2-USA, 2-MENA, 1- CA)
- ✓ **1 FDF** (USA)



## R&D Pipeline

- ✓ **19 Products**

- **Europe**

- Renewed EUGMP certification for Spanish manufacturing plant
- Good business performance, led by Exports & Companion Animal Segment
- Partnered with VetViva Richter for Canine Heart therapy
- Initiated direct companion animal sales activities in Italy.

- **Emerging Markets**

- Turkey: Setup R&D center for injectable portfolio.
- Tulaject: Launched in Brazil with receipt of Marketing Authorization (MA) for Mexico.

- **India**

- Expansion of Cattle field team.
- Partnership with Boehringer Ingelheim for distribution and promotion of companion animal portfolio.

# Merger Update



## Merger – Process Update

### Merger process status update

- Merger has been approved by all regulatory authorities, and the merger is in effect
- **Focus on synergy realization for next 12 months**
- **The process is well on track as per estimated timelines**





Area	Key Ideation Action Items	Progress
<b>R&amp;D</b>	<ul style="list-style-type: none"> <li>R&amp;D teams to be co-located; projects to be ideated on NPD &amp; cost improvement</li> <li>QA &amp; Testing movement to on-site from 3<sup>rd</sup> party location</li> </ul>	<p>API R&amp;D fully integrated leading to accelerated development</p> <ul style="list-style-type: none"> <li>6 New animal health products developed/validated</li> <li>5 Cost improvement projects completed.</li> <li>Implementation for on-site testing initiated.</li> </ul> <p>Regulatory filing initiated</p>
<b>Manufacturing</b>	<ul style="list-style-type: none"> <li>Utilize available low-cost capacity through the group; action plan created</li> <li>Procurement synergies identified</li> </ul>	<ul style="list-style-type: none"> <li>6 Intermediates validated at Viyash sites, which were procured from external sources</li> <li>New production block created and got EU approval; commercialization already started</li> <li>CEP Approval received for large volume product from dedicated facility</li> </ul>
<b>Sales</b>	<ul style="list-style-type: none"> <li>Leverage key relationships of both companies.</li> </ul>	<p>Business ramped up with integration benefits.</p>
<b>Others</b>	<ul style="list-style-type: none"> <li>Assess shared administrative &amp; support functions</li> </ul>	<p>All support functions' integration completed</p>

***For details, feel free to contact:***

**Yoshita Vora**


**Company Secretary**

 +91 22 4111 4777

 investorrelations@viyash.com

**Abhishek Singhal**

**Investor Relations Consultant**

 abhishek@arunya.co.in

***Registered Office: Plot No.290, Srivalli's Corporate, Road No.6, Kakatiya Hills, Madhapur Hyderabad Rangareddy TG 500081, India***

**Websites: [www.viyash.com](http://www.viyash.com) | CIN: L99999TS1985PLC196357 | BSE Code:512529 | NSE: VIYASH**

**ISIN: INE807F01027**

*Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. SeQuent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.*



# Thank You

Plot No.290, Srivalli's Corporate, Road No.6, Kakatiya Hills, Madhapur Hyderabad Rangareddy TG 500081, India

[info@viyash.com](mailto:info@viyash.com) | [www.viyash.com](http://www.viyash.com)

Copyright © 2021. Viyash. All Rights Reserved.